StockData
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) income statement

TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30711% above fair value
$48.30−1.94 (-3.86%)

Close on Nov 19, 2026Market cap $4.55BP/E –Yield –

Travere Therapeutics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
98.6%
Operating margin
-6.8%
Net margin
-7.4%
Return on equity, FY2026
-29.4%

Financial strength

Current ratio
4.05
Debt to equity
–
Debt to assets
–
Cash to current liabilities
77.4%

Valuation

P/E ratio
–
Price to sales
7.70
Price to book
185.66
Dividend yield
–

See a number that looks wrong?